---
document_datetime: 2023-09-21 21:41:10
document_pages: 9
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/spherox-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: spherox-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 7.3482937
conversion_datetime: 2025-12-27 15:40:18.652655
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Spherox

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IAIN/0031/G          | This was an application for a group of variations. A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release A.5.a - Administrative change - Change in the name | 16/02/2023                          |                                             | SmPC, Annex II, Labelling and PL |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | and/or address of a manufacturer/importer responsible for batch release A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.1 - Administrative change - Change in the name and/or address of the MAH   |            |            |                        |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| PSUSA/10630 /202207 | Periodic Safety Update EU Single assessment - spheroids of human autologous matrix-associated chondrocytes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 09/02/2023 | n/a        |                        | PRAC Recommendation - maintenance |
| T/0030              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 05/12/2022 | 10/01/2023 | SmPC, Labelling and PL |                                   |
| IB/0028             | B.II.b.z - Change in manufacture of the Finished Product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 02/09/2022 | n/a        |                        |                                   |
| IB/0027             | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                     | 08/08/2022 | n/a        |                        |                                   |

<div style=\"page-break-after: always\"></div>

| R/0024              | Renewal of the marketing authorisation.                                                                                                                                                                                                      | 24/02/2022   | 29/04/2022   | SmPC, Annex II, Labelling and PL   | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Spherox in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0026             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 07/03/2022   | n/a          |                                    |                                                                                                                                                                                                                                                                         |
| PSUSA/10630 /202107 | Periodic Safety Update EU Single assessment - spheroids of human autologous matrix-associated chondrocytes                                                                                                                                   | 10/02/2022   | n/a          |                                    | PRAC Recommendation - maintenance                                                                                                                                                                                                                                       |
| II/0020             | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                               | 20/05/2021   | 28/06/2021   | SmPC and PL                        | Please refer to Scientific Discussion ' Product Name-H-C- Product Number-II-0020 '                                                                                                                                                                                      |
| IB/0023             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                 | 21/05/2021   | n/a          |                                    |                                                                                                                                                                                                                                                                         |
| II/0022             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                            | 22/04/2021   | 28/06/2021   | SmPC and Annex II                  |                                                                                                                                                                                                                                                                         |
| II/0021/G           | This was an application for a group of variations.                                                                                                                                                                                           | 22/04/2021   | 28/06/2021   | Annex II and                       |                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.3 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing for a biol/immunol product and any of the test methods is a biol/immunol/immunochemical method B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a   |            |            | PL          |                                                          |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------|
| PSUSA/10630 /202007 | Periodic Safety Update EU Single assessment - spheroids of human autologous matrix-associated chondrocytes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 11/02/2021 | n/a        |             | PRAC Recommendation - maintenance                        |
| PSUSA/10630         | Periodic Safety Update EU Single assessment -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 17/09/2020 | 20/11/2020 | SmPC and PL | Refer to Scientific conclusions and grounds recommending |

<div style=\"page-break-after: always\"></div>

| /202001   | spheroids of human autologous matrix-associated chondrocytes                                                                                                                                                                                                                                                                                                                                                                      |            |            |             | the variation to terms of the Marketing Authorisation(s) ' for PSUSA/10630/202001.                                                                                                                                                                                                                                                                                                                                                                               |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0018/G | This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.II.e.3.b - Change in test procedure for the immediate packaging of the finished product - Other changes to a test procedure (including replacement or addition) | 01/10/2020 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0016   | The RMP has been updated in accordance with GVP Module V Rev. 2 template. The educational materials described in Annex II have been updated with editorial changes accordingly. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                     | 28/05/2020 | 09/10/2020 | Annex II    | The RMP has been updated in accordance with GVP Module V Rev. 2 template. No new safety concerns have been documented and therefore no new risk minimisation measures are required. The educational materials described in Annex II have been updated with editorial changes: only information on the key elements of the training material for surgeons/ other HCPs and the prescriber checklist is provided, not the entire document of the training material. |
| II/0015   | Update of section 4.8 and 5.1 of the SmPC and relevant sections of the PL following the 48-month follow up data for trial cod 16 HS 13, a study assessing the long-term efficacy and safety of Spherox. C.I.4 - Change(s) in the SPC, Labelling or PL due to                                                                                                                                                                      | 28/05/2020 | 09/10/2020 | SmPC and PL | MAH submitted the 48-month follow-up data for study cod 16 HS 13. The ongoing Study cod 16 HS 13 is a prospective, randomised, open-label (central reading by blinded radiologist) active-controlled, multicentre trial to compare the efficacy and safety of treatment with ACT3D- CS to microfracture in subjects with cartilage defects of the knee with a defect size between 1 and 4 cm2. Patients will                                                     |

<div style=\"page-break-after: always\"></div>

|                     | new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                 |            |     | be followed for 60 months. Overall, the Phase 3 trial with microfracture (MF) as comparator continued to indicate consistent outcomes for Spherox compared to MF. Updated safety results for study 16 HS 13 (48 month follow-up) were also provided. The overall safety profile for Spherox remains unchanged. The PI was updated to reflect bone marrow oedema as common adverse reaction and to reflect the study results.   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10630 /201907 | Periodic Safety Update EU Single assessment - spheroids of human autologous matrix-associated chondrocytes                                                                                                                                   | 16/01/2020 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                              |
| IB/0014             | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place   | 14/01/2020 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                |
| IB/0012             | B.II.e.z - Change in container closure system of the Finished Product - Other variation                                                                                                                                                      | 08/01/2020 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                |
| IA/0013             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 12/12/2019 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                |
| IA/0010             | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information                                                               | 17/10/2019 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| II/0008   | The MAH has submitted a prospective process validation study using batches manufactured with a well-controlled process and to collect quality data from a sufficient number of batches to demonstrate consistency, quality and genetic stability of the cells in the finished product which was a condition to the Marketing Authorisation. Annex II of the Marketing Authorisation is updated to remove the corresponding obligation. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required   | 19/09/2019   | 09/10/2020   | Annex II    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0005/G | This was an application for a group of variations. Update of sections 4.8 and 5.1 of the SmPC to reflect the study results of the 36-month follow up data for trial cod 16 HS 13 and the final study report with 60- month follow-up data for trial cod 16 HS 14. Study cod 16 HS 13, is a Prospective, randomised, open label, multicentre Phase-III clinical trial to compare the efficacy and safety of the treatment with the autologous chondrocyte transplantation product co.don chondrosphere (ACT3D-CS) with microfracture in subjects with cartilage defects of the knee with a defect size between 1 and 4 cm2.                                                                                                              | 19/09/2019   | 09/10/2020   | SmPC and PL | Results from both studies confirmed that outcomes were consistent with previous submitted data These results were reflected in section 5.1. In study cod 16 HS 14, the primary efficacy variable, change of overall KOOS from baseline at 60 months, was on average (SD) 19.9±18.0, very similar to the 48-month data (mean: 20.1 ±17.3), showing a clinically relevant and sustained improvement in KOOS. In line with previous reports, no relevant differences between the low, medium, and high dose were noted. KOOS subscores were also consistent with previous data. MOCART scores at 60 months were also consistent with previous data i.e. maintained improvement with no evidence of a dose response. The overall MOCART score at 60 months for |

<div style=\"page-break-after: always\"></div>

|                     | Study cod 16 HS 14, is a Prospective, randomised, open label, multicentre Phase-II clinical trial to investigate the efficacy and safety of the treatment of large defects (4-10 cm2) with three different doses of the autologous chondrocyte transplantation product co.don chondrosphere (ACT3D-CS) in subjects with cartilage defects of the knee. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |     | all doses combined was 75.1±14.5, similar to previous data. In study cod 16 HS 13 results for overall KOOS and change of overall KOOS from baseline at 36 months were presented. For the patients treated with ACT3D-CS the mean overall KOOS score was 83.2 ± 14.9 as compared with 76.3 ± 17.1 for MF. The mean change from baseline was +26.6 ± 16.2 for patients in the ACT3D-CS group and 24.5 ± 16.7 for those in the MF group. Overall, this is in line with the previous data. KOOS subscores also showed a pattern that was consistent with previous data. The MOCART score at 36 months was respectively 75.0 ± 13.4 and 78.3 ± 12.6 for the ACT3D-CS and microfracture groups showing consistency over time. No new safety concerns were identified in the data presented for both studies. Section 4.8 of the SmPC and relevant section of the PL was updated to differentiate any   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10630 /201901 | Periodic Safety Update EU Single assessment - spheroids of human autologous matrix-associated chondrocytes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 11/07/2019 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| IA/0006/G           | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder                                                                                                                                                                                          | 27/03/2019 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|                     | or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                       |            |            |             |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| PSUSA/10630 /201807 | Periodic Safety Update EU Single assessment - spheroids of human autologous matrix-associated chondrocytes                                                                                                                                                                                     | 17/01/2019 | n/a        |             | PRAC Recommendation - maintenance |
| PSUSA/10630 /201801 | Periodic Safety Update EU Single assessment - spheroids of human autologous matrix-associated chondrocytes                                                                                                                                                                                     | 12/07/2018 | n/a        |             | PRAC Recommendation - maintenance |
| II/0002/G           | This was an application for a group of variations. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data         | 28/06/2018 | 11/04/2019 | SmPC and PL |                                   |
| II/0001             | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required | 26/04/2018 | 11/04/2019 | Annex II    |                                   |